Pi3K
Showing 26 - 50 of >10,000
Breast Cancer, PI3K, Alpelisib Trial in France (Alpelisib, Chemotherapy)
Active, not recruiting
- Breast Cancer, PI3K, Alpelisib
-
Angers, France
- +13 more
Mar 8, 2022
Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation, Vascular Malformations Trial in Parkville (Alpelisib,
Not yet recruiting
- Slow-Flow Vascular Malformation
- +17 more
-
Parkville, Victoria, AustraliaThe Royal Children's Hospital
Aug 7, 2023
Activated PI3K-delta Syndrome, Immunodeficiency Primary Trial in Shanghai (Rapamycin)
Recruiting
- Activated PI3K-delta Syndrome
- Immunodeficiency Primary
-
Shanghai, Shanghai, China
- +1 more
Mar 21, 2022
Peripheral T-Cell Lymphoma Trial in Zhengzhou (Parsaclisib, Chidamide)
Not yet recruiting
- Peripheral T-Cell Lymphoma
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Dec 26, 2021
Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage
Completed
- Metastatic Breast Cancer
- +2 more
- Control group
- Case group
- (no location specified)
Jun 16, 2022
Solid Tumor, Adult Trial in Seoul (TAS-117)
Completed
- Solid Tumor, Adult
-
Seoul, Korea, Republic ofSeverance Hospital, Yonsei University Health System
Apr 21, 2021
Breast Cancer Trial in United States (Benralizumab, fulvestrant or AIs) and PI3K inhibition (alpelisib))
Recruiting
- Breast Cancer
- Benralizumab
- fulvestrant or AIs) and PI3K inhibition (alpelisib)
-
Stanford, California
- +8 more
Aug 1, 2023
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma Trial in Worldwide (Ribociclib, Everolimus)
Not yet recruiting
- High Grade Glioma
- +8 more
-
Aurora, Colorado
- +17 more
May 2, 2023
Esophageal Cancer Trial in Hat yai (BKM120)
Terminated
- Esophageal Cancer
-
Hat yai, Songkhla, ThailandSongklanagarind Hospital, Prince of Songkla University
Oct 3, 2021
Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders Trial (ARQ 092)
No longer available
- Proteus Syndrome
- +2 more
- ARQ 092
- (no location specified)
Jul 31, 2021
Lymphoma, Small Lymphocytic, Lymphoma, Lymphoma, Non-Hodgkin Trial in United States (duvelisib, PI3K inhibitor)
Terminated
- Lymphoma, Small Lymphocytic
- +4 more
- duvelisib
- PI3K inhibitor
-
Little Rock, Arkansas
- +10 more
Mar 15, 2021
Follicular Lymphoma, Endometrial Cancer Trial in New York (Copanlisib, Ketogenic Diet)
Recruiting
- Follicular Lymphoma
- Endometrial Cancer
- Copanlisib
- Ketogenic Diet
-
New York, New York
- +2 more
Nov 24, 2021
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With
Completed
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- +35 more
- PI3K inhibitor BKM120
- cetuximab
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
Sep 14, 2021
Salivary Gland Cancer, Metastatic, Advanced Trial in Toronto (Selinexor, EGFR or HER2 Inhibitor, FGFR Inhibitor)
Recruiting
- Salivary Gland Cancer
- +3 more
- Selinexor
- +6 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Feb 18, 2022
Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)
Recruiting
- Chronic Lymphocytic Leukemia
- +6 more
- Copanlisib
- Nivolumab
-
Duarte, California
- +2 more
Mar 9, 2022
Breast Cancer Trial in Los Angeles, Bronx (Gedatolisib, Faslodex, Palbociclib)
Active, not recruiting
- Breast Cancer
- Gedatolisib
- +3 more
-
Los Angeles, California
- +1 more
Jan 25, 2022
Low Grade Glioma, World Health Organization (WHO) Grade II Astrocytomas, Oligodendrogliomas Trial in San Francisco (Everolimus,
Terminated
- Low Grade Glioma
- +3 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Nov 3, 2021
Glioblastoma, Adult Trial in United States (Paxalisib (GDC-0084))
Active, not recruiting
- Glioblastoma, Adult
- Paxalisib (GDC-0084)
-
Los Angeles, California
- +5 more
Aug 16, 2022
Activated PI3K-delta Syndrome Trial in Cambridge (Nemiralisib)
Completed
- Activated PI3K-delta Syndrome
-
Cambridge, United KingdomGSK Investigational Site
May 26, 2021
Follicular Lymphoma Trial in Germany (Copanlisib, Obinutuzumab)
Recruiting
- Follicular Lymphoma
-
München, Bavaria, Germany
- +39 more
May 19, 2022
Advanced Gastric Adenocarcinoma Trial in Seoul (GSK2636771, Paclitaxel)
Completed
- Advanced Gastric Adenocarcinoma
-
Seoul, Korea, Republic ofSeverance Hospital, Yonsei University Health System, Yonsei Canc
Apr 21, 2021
Refractory/Recurrent Primary CNS Lymphoma (PCNSL) Trial in United States (Ibrutinib, Copanlisib)
Recruiting
- Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
-
Basking Ridge, New Jersey
- +6 more
Jul 27, 2022